Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD

Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 16.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company’s stock after selling 2,975,000 shares during the period. Amicus Therapeutics makes up about 1.5% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 20th biggest holding. Avoro Capital Advisors LLC owned approximately 4.87% of Amicus Therapeutics worth $118,397,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of FOLD. Goldman Sachs Group Inc. boosted its position in Amicus Therapeutics by 7.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company’s stock valued at $22,061,000 after buying an additional 194,213 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Amicus Therapeutics by 11.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company’s stock valued at $8,751,000 after purchasing an additional 113,803 shares in the last quarter. Intech Investment Management LLC grew its stake in Amicus Therapeutics by 37.1% during the 1st quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company’s stock valued at $1,395,000 after purchasing an additional 46,218 shares in the last quarter. Strs Ohio purchased a new stake in Amicus Therapeutics during the 1st quarter worth approximately $30,000. Finally, Bank of Montreal Can acquired a new position in shares of Amicus Therapeutics in the 2nd quarter valued at approximately $144,000.

Insider Buying and Selling

In related news, insider David Michael Clark sold 25,643 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $11.00, for a total transaction of $282,073.00. Following the completion of the sale, the insider directly owned 271,332 shares of the company’s stock, valued at approximately $2,984,652. This represents a 8.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 77,926 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. This represents a 6.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 226,711 shares of company stock worth $2,887,822 over the last three months. 2.20% of the stock is owned by company insiders.

Analyst Ratings Changes

FOLD has been the subject of several recent analyst reports. Jefferies Financial Group reissued a “hold” rating and set a $14.50 price objective (down from $16.00) on shares of Amicus Therapeutics in a report on Thursday, January 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a research report on Monday, December 29th. Cantor Fitzgerald downgraded shares of Amicus Therapeutics from an “overweight” rating to a “hold” rating and decreased their price objective for the stock from $21.00 to $14.50 in a report on Friday, December 19th. Guggenheim downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 5th. Finally, TD Cowen downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a research report on Monday, December 22nd. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.39.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $14.37 on Friday. The business has a fifty day simple moving average of $14.32 and a 200-day simple moving average of $11.15. The company has a market cap of $4.51 billion, a price-to-earnings ratio of -179.63 and a beta of 0.43. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $14.39. The company has a quick ratio of 1.88, a current ratio of 2.84 and a debt-to-equity ratio of 1.43.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.03). Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The business had revenue of $185.21 million during the quarter, compared to analyst estimates of $185.00 million. During the same period last year, the business earned $0.09 EPS. The business’s quarterly revenue was up 23.7% on a year-over-year basis. Sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.15 EPS for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.